The clinical utility of FibroScan® as a noninvasive diagnostic test for liver disease
Julius Wilder,1,2 Keyur Patel1,21Division of Gastroenterology, Duke University School of Medicine, 2Duke Clinical Research Institute, Durham, NC, USAAbstract: An important aspect of managing chronic liver disease is assessing for evidence of fibrosis. Historically, this has been accomplished using...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/beb8e85e185041509442cefbb2ee8b35 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sumario: | Julius Wilder,1,2 Keyur Patel1,21Division of Gastroenterology, Duke University School of Medicine, 2Duke Clinical Research Institute, Durham, NC, USAAbstract: An important aspect of managing chronic liver disease is assessing for evidence of fibrosis. Historically, this has been accomplished using liver biopsy, which is an invasive procedure associated with risk for complications and significant sampling and observer error, limiting the accuracy for determination of fibrosis stage. Hence, several serum biomarkers and imaging methods for noninvasive assessment of liver fibrosis have been developed. In this article, we review the current literature on an important noninvasive imaging modality to measure tissue elastography (FibroScan®). This ultrasound-based technique is now increasingly available in many countries and has been shown to be a reliable and safe noninvasive means of assessing disease severity in chronic liver disease of varying etiology.Keywords: elastography, ultrasound, fibrosis, cirrhosis |
---|